Abstract
To review the available published data regarding the incidence, mechanisms of pathogenesis, clinical presentations and management of pneumonitis caused by anti-cancer treatments (radiotherapy (RT) and systemic agents) that are included in the guidelines of the treatment of breast cancer (BC) and address the issues on the current grading classification of pneumonitis. A literature search was performed between July and October 2013 using PubMed for papers published from January 1989 to October 2013. Any clinical trial, case report, case series, meta-analysis or systematic review that reported on pulmonary toxicity of any BC therapeutic modality was included (only papers published in English). Most of anticancer treatments currently used in the management of BC may induce some degree of pneumonitis that is estimated to have an incidence of 1–3 %. There is an obvious distinction between chemotherapy- and targeted treatment-related lung toxicity. Moreover, the current classification of pneumonitis needs to be modified as there is a clear diversity in grade 2. As pneumonitis is relatively common and reported as side effect of new anticancer agents, physicians need to be aware of the clinical and radiological manifestations of drug- and RT-induced toxicities in patients with BC. A key recommendation is the subdivision of grade 2 cases to two subgroups. We provide an algorithm, along with real life cases as managed in the breast Unit of Royal Marsden Hospital, with the aim to guide physicians in managing all possible eventualities that may come across in clinical practise.
Similar content being viewed by others
References
Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. doi:10.1093/annonc/mdt284
Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91(Suppl 2):S18–S23. doi:10.1038/sj.bjc.6602063
de Castro G Jr, Awada A (2006) Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). Curr Opin Oncol 18(4):307–315. doi:10.1097/01.cco.0000228733.55132.ea
Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133(2):528–538. doi:10.1378/chest.07-0851
Camus PH, Foucher P, Bonniaud PH, Ask K (2001) Drug-induced infiltrative lung disease. Eur Respir J Suppl 32:93s–100s
Rosenow EC III, Limper AH (1995) Drug-induced pulmonary disease. Semin Respir Infect 10(2):86–95
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. J Clin Oncol 27(27):4536–4541. doi:10.1200/JCO.2008.21.3033
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. doi:10.1056/NEJMoa1109653
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630–2637. doi:10.1200/JCO.2008.18.8391
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724. doi:10.1200/JCO.2011.39.0708
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. doi:10.1016/S0140-6736(11)61629-2
Buchanan CL, Dorn PL, Fey J, Giron G, Naik A, Mendez J, Murphy C, Sclafani LM (2006) Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg 203(4):469–474. doi:10.1016/j.jamcollsurg.2006.06.015
Oie Y, Saito Y, Kato M, Ito F, Hattori H, Toyama H, Kobayashi H, Katada K (2013) Relationship between radiation pneumonitis and organizing pneumonia after radiotherapy for breast cancer. Radiat Oncol 8:56. doi:10.1186/1748-717X-8-56
Vogelius IR, Bentzen SM (2012) A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 51(8):975–983. doi:10.3109/0284186X.2012.718093
White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182(3):396–403. doi:10.1164/rccm.200911-1720OC
Limper AH (2004) Chemotherapy-induced lung disease. Clin Chest Med 25(1):53–64. doi:10.1016/S0272-5231(03)00123-0
Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL (2002) Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 57(4):292–299. doi:10.1053/crad.2001.0792
Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41–56. doi:10.1148/radiol.10092129
von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S (2007) Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 30(6):320–323. doi:10.1159/0000101517
Post MC, Grutters JC, Verzijlbergen JF, Biesma DH (2007) PET scintigraphy of etoposide-induced pulmonary toxicity. Clin Nucl Med 32(9):683–684. doi:10.1097/RLU.0b013e318123f78d
Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS (2009) [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma 50(6):904–911. doi:10.1080/10428190902919200
Yerushalmi R, Kramer MR, Rizel S, Sulkes A, Gelmon K, Granot T, Neiman V, Stemmer SM (2009) Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol 20(3):437–440. doi:10.1093/annonc/mdn652
Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE, Fernando IN, Ritchie DM, Earl HM, Poole CJ (2008) tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. Br J Cancer 99(4):597–603. doi:10.1038/sj.bjc.6604538
Dimopoulou I, Galani H, Dafni U, Samakovii A, Roussos C, Dimopoulos MA (2002) A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 94(2):452–458. doi:10.1002/cncr.10182
Bossi G, Cerveri I, Volpini E, Corsico A, Baio A, Corbella F, Klersy C, Arico M (1997) Long-term pulmonary sequelae after treatment of childhood Hodgkin’s disease. Ann Oncol 8(Suppl 1):19–24
Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P (2004) Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 25(3):479–519. doi:10.1016/j.ccm.2004.05.006
Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N (2004) Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1):93–104. doi:10.1016/j.lungcan.2004.01.010
Ochoa R, Bejarano PA, Gluck S, Montero AJ (2012) Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep 6(1):413. doi:10.1186/1752-1947-6-413
Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA (2004) Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 96(22):1676–1681. doi:10.1093/jnci/djh315
McDonald S, Rubin P, Phillips TL, Marks LB (1995) Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 31(5):1187–1203. doi:10.1016/0360-3016(94)00429-O
Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, Hernando ML, Lucas D, Piepgrass A, Prosnitz LR (2002) Technical factors associated with radiation pneumonitis after local ± regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 52(1):137–143
Blom-Goldman U, Svane G, Wennberg B, Lidestahl A, Lind PA (2007) Quantitative assessment of lung density changes after 3-D radiotherapy for breast cancer. Acta Oncol 46(2):187–193. doi:10.1080/02841860600949586
Deantonio L, Gambaro G, Beldi D, Masini L, Tunesi S, Magnani C, Krengli M (2010) Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol 5:112. doi:10.1186/1748-717X-5-112
Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341. doi:10.1016/S1470-2045(08)70077-9
Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107. doi:10.1016/S0140-6736(08)60348-7
Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, Lada B, Lukka H, Perera F, Fyles A, Laukkanen E, Gulavita S, Benk V, Szechtman B (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94(15):1143–1150
Fragkandrea I, Kouloulias V, Mavridis P, Zettos A, Betsou S, Georgolopoulou P, Sotiropoulou A, Gouliamos A, Kouvaris I (2013) Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study. Hippokratia 17(3):233–238
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. doi:10.1016/S1470-2045(13)70386-3
Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN (2001) Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93(23):1806–1811
Hanna YM, Baglan KL, Stromberg JS, Vicini FA, Decker AD (2002) Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 8(3):149–153
Varga Z, Cserhati A, Kelemen G, Boda K, Thurzo L, Kahan Z (2011) Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 80(4):1109–1116. doi:10.1016/j.ijrobp.2010.03.044
Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS (2005) Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23(1):24–29. doi:10.1200/JCO.2005.01.198
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106. doi:10.1016/S0140-6736(05)67887-7
Epperly M, Bray J, Kraeger S, Zwacka R, Engelhardt J, Travis E, Greenberger J (1998) Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther 5(2):196–208. doi:10.1038/sj.gt.3300580
Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL (1998) Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41(5):1029–1035
Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL (2003) Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 56(4):988–995
Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, Finkelstein JN, Rubin P, Okunieff P (2002) Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12(1 Suppl 1):26–33
Nozaki M, Kagami Y, Mitsumori M, Hiraoka M (2012) A multicenter investigation of late adverse events in Japanese women treated with breast-conserving surgery plus conventional fractionated whole-breast radiation therapy. Jpn J Clin Oncol 42(6):522–527. doi:10.1093/jjco/hys050
Katayama N, Sato S, Katsui K, Takemoto M, Tsuda T, Yoshida A, Morito T, Nakagawa T, Mizuta A, Waki T, Niiya H, Kanazawa S (2009) Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Int J Radiat Oncol Biol Phys 73(4):1049–1054. doi:10.1016/j.ijrobp.2008.05.050
Kubo A, Osaki K, Kawanaka T, Furutani S, Ikushima H, Nishitani H (2009) Risk factors for radiation pneumonitis caused by whole breast irradiation following breast-conserving surgery. J Med Invest 56(3–4):99–110
Kano A, Ujita M, Kobayashi M, Sunakawa Y, Shirahama J, Harada T, Kanehira C, Fukuda K (2012) Radiographic and CT features of radiation-induced organizing pneumonia syndrome after breast-conserving therapy. Jpn J Radiol 30(2):128–136. doi:10.1007/s11604-011-0024-9
Ma LD, Taylor GA, Wharam MD, Wiley JM (1993) “Recall” pneumonitis: adriamycin potentiation of radiation pneumonitis in two children. Radiology 187(2):465–467
Schwarte S, Wagner K, Karstens JH, Bremer M (2007) Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 183(4):215–217. doi:10.1007/s00066-007-1688-z
Schweitzer VG, Juillard GJ, Bajada CL, Parker RG (1995) Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 76(6):1069–1072
Bourgier C, Massard C, Moldovan C, Soria JC, Deutsch E (2011) Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect? Ann Oncol 22(2):485–486. doi:10.1093/annonc/mdq741
Vahid B, Marik PE (2008) Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies. Can Respir J 15(4):211–216
Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120(2):617–624
Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16(10):3426–3432
Briasoulis E, Pavlidis N (2001) Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 6(2):153–161
Wang GS, Yang KY, Perng RP (2001) Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 85(9):1247–1250. doi:10.1054/bjoc.2001.2071
Malik SW, Myers JL, DeRemee RA, Specks U (1996) Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 154(6 Pt 1):1851–1856. doi:10.1164/ajrccm.154.6.8970380
Shaib W, Lansigan F, Cornfeld D, Syrigos K, Saif MW (2008) Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP 9(6):708–714
Miettinen PJ, Warburton D, Bu D, Zhao JS, Berger JE, Minoo P, Koivisto T, Allen L, Dobbs L, Werb Z, Derynck R (1997) Impaired lung branching morphogenesis in the absence of functional EGF receptor. Dev Biol 186(2):224–236. doi:10.1006/dbio.1997.8593
Dillman RO (1999) Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18(4):465–471
Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77(8):1215–1220
Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H (2001) Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72(5):787–790
Albiges L, Chamming’s F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P (2012) Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 23(8):1943–1953. doi:10.1093/annonc/mds115
Chilosi M, Pea M, Martignoni G, Brunelli M, Gobbo S, Poletti V, Bonetti F (2009) Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 22(2):161–166. doi:10.1038/modpathol.2008.189
Hamada K, Nagai S, Kitaichi M, Jin G, Shigematsu M, Nagao T, Sato A, Mishima M (2003) Cyclophosphamide-induced late-onset lung disease. Intern Med 42(1):82–87
Segura A, Yuste A, Cercos A, Lopez-Tendero P, Girones R, Perez-Fidalgo JA, Herranz C (2001) Pulmonary fibrosis induced by cyclophosphamide. Ann Pharmacother 35(7–8):894–897
Hoyt DG, Lazo JS (1989) Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. J Pharmacol Exp Ther 249(1):38–43
Stentoft J (1987) Progressive pulmonary fibrosis complicating cyclophosphamide therapy. Acta Med Scand 221(4):403–407
Mendez M, Barriga F, Garcia C, Holmgren NL, Gonzalez S, Sanchez I (2000) Bronchiolitis obliterans with organizing pneumonia secondary to chemotherapy in a child with primary pericardial sarcoma. Rev Med Chil 128(6):633–640
Jacobs C, Slade M, Lavery B (2002) Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol) 14(3):262
Dang CT, D’Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA (2004) Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 10(17):5754–5761. doi:10.1158/1078-0432.CCR-04-0634
Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ (2003) Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21(5):843–850
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O’Brien P, Shepherd LE (2010) Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28(1):77–82. doi:10.1200/JCO.2009.22.1077
Couderc LJ, Stelianides S, Frachon I, Stern M, Epardeau B, Baumelou E, Caubarrere I, Hermine O (1999) Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Respir Med 93(1):65–68
Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B (2006) Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer 16(Suppl 1):391–393. doi:10.1111/j.1525-1438.2006.00222.x
Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24(31):4963–4970. doi:10.1200/JCO.2005.05.0294
Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16(1):159–164
Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17(3):372–379. doi:10.1093/annonc/mdj057
Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non overexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649. doi:10.1200/JCO.2007.11.6699
Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, Nishiwaki Y, Niitani H, Sakuma A (1994) A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 11(5–6):385–391
Igishi T, Shigeoka Y, Yasuda K, Suyama H, Katayama S, Sugitani A, Matsumoto S, Yamamoto M, Ueda Y, Takeda K, Sumikawa T, Sako T, Kodani M, Hitsuda Y, Shimizu E (2009) UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study. J Thorac Oncol 4(3):376–382. doi:10.1097/JTO.0b013e3181989dfc
Yanagitani N, Shimizu Y, Kaira K, Tatsuno S, Sunaga N, Ishizuka T, Mori M (2008) Pulmonary toxicity associated with vinorelbine-based chemotherapy in breast cancer. Gan To Kagaku Ryoho 35(9):1619–1621
Radzikowska E, Szczepulska E, Chabowski M, Bestry I (2003) Organising pneumonia caused by transtuzumab (herceptin) therapy for breast cancer. Eur Respir J 21(3):552–555
Vahid B, Mehrotra A (2006) Trastuzumab (herceptin)-associated lung injury. Respirology 11(5):655–658. doi:10.1111/j.1440-1843.2006.00907.x
Bettini AC, Tondini C, Poletti P, Caremoli ER, Guerra U, Labianca R (2008) A case of interstitial pneumonitis associated with Guillain-Barre syndrome during administration of adjuvant trastuzumab. Tumori 94(5):737–741
Pepels MJ, Boomars KA, van Kimmenade R, Hupperets PS (2009) Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res Treat 113(3):609–612. doi:10.1007/s10549-008-9966-8
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914–923. doi:10.1016/S0140-6736(11)60070-6
Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin—a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81(2):163–184. doi:10.1016/j.critrevonc.2011.03.002
Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S (2012) A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23(6):1441–1448. doi:10.1093/annonc/mdr444
O’Donnell PH, Dolan ME (2009) Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15(15):4806–4814. doi:10.1158/1078-0432.CCR-09-0344
Mack PC, Gandara DR, Lara PN Jr (2012) Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach. Expert Rev Anticancer Ther 12(12):1591–1596. doi:10.1586/era.12.135
Nakagawa M, Nishimura T, Teramukai S, Tada H, Tanaka F, Yanagihara K, Furuse K, Wada H, Fukushima M (2009) Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. BMC Res Notes 2:157. doi:10.1186/1756-0500-2-157
Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L (2012) Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract 18(2):311–315. doi:10.1177/1078155211429384
Cook-Bruns N (2001) Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2):58–66
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. doi:10.1056/NEJMoa052122
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. doi:10.1056/NEJMoa1209124
Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30(26):3234–3241. doi:10.1200/JCO.2011.40.5902
Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O’Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398–405. doi:10.1200/JCO.2010.29.5865
Yip AY, Tse LA, Ong EY, Chow LW (2010) Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 21(5):487–493. doi:10.1097/CAD.0b013e3283388eaf
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33):5538–5546. doi:10.1200/JCO.2009.23.3734
Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schutte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S (2010) An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 21(3):474–480. doi:10.1093/annonc/mdp373
Peterson ME (2013) Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 21(8):2341–2349. doi:10.1007/s00520-013-1826-3
Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E (2012) Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 51(7):873–879. doi:10.3109/0284186X.2012.705019
Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2):447–455. doi:10.1007/s10549-010-1260-x
Schwarzlose-Schwarck S, Scholz CW, Regierer AC, Martus P, Neumann C, Habbel P, Liu H, Zang C, Schefe JH, Schulz CO, Possinger K, Eucker J (2012) The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer—a phase I trial. Anticancer Res 32(8):3435–3441
Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT (2012) A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378–2384. doi:10.1002/cncr.26571
Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ (2011) Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29(23):3126–3132. doi:10.1200/JCO.2010.32.2321
Andre F, Campone M, O’Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110–5115. doi:10.1200/JCO.2009.27.8549
Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK (2012) Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 48(10):1519–1524. doi:10.1016/j.ejca.2012.03.012
Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20(10):1674–1681. doi:10.1093/annonc/mdp060
White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH (2009) Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 4(11):1357–1363. doi:10.1097/JTO.0b013e3181ba20b1
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523. doi:10.1056/NEJMoa1009290
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28(1):69–76. doi:10.1200/JCO.2009.24.2669
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005–2012. doi:10.1016/S0140-6736(11)61742-X
Ito Y, Noguchi S, Deleu I, Baselga J, Hortobagyi GN, Bachelot TD, Masuda N, Pistilli B, Pritchard KI, Iwata H, Gnant M, Eakle JF, Csõszi T, Srimuninnimit V, Puttawibul P, Roila F, Panneerselvam A, Taran T, Sahmoud T, Rugo HS (2013) Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. J Clin Oncol 31, 2013 (suppl; abstr 561)
Common Terminology Criteria for Adverse Events (CTCAE) (2009) http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf
Yazbeck VY, Villaruz L, Haley M, Socinski MA (2013) Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Cancer J 19(3):231–237. doi:10.1097/PPO.0b013e31829453fb
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Omarini, C., Thanopoulou, E. & Johnston, S.R.D. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat 146, 245–258 (2014). https://doi.org/10.1007/s10549-014-3016-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-3016-5